Related Experiment Videos
[Specific immunotherapy with cancer vaccines]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 4, 2000
Summary
Researchers identified cancer-specific antigens and developed peptide vaccines targeting esophageal cancer. While early trials show promise, overcoming tumor immune evasion is crucial for successful cancer vaccine therapy.
Area of Science:
- Molecular biology
- Immunology
- Oncology
Context:
- Advances in molecular biology and gene technology have identified numerous cancer-specific antigens.
- Cytotoxic T lymphocytes (CTLs) restricted by HLA class I molecules play a key role in cancer immunotherapies.
Purpose:
- To identify novel cancer-specific antigens and develop effective cancer vaccine therapies.
- To establish and utilize human leukocyte antigen (HLA)-restricted, cancer-specific CTLs for immunotherapy.
Summary:
- Established HLA-A24- and A26-restricted, cancer-specific CTLs from an esophageal cancer patient.
- Identified SART-1 and cyclophilin B genes encoding antigenic epitopes recognized by CTLs.
- Initiated Phase I trials with peptide vaccines, observing increased CTL precursor frequency in vitro.
Impact:
- Identified SART-1 and cyclophilin B as targets for cancer immunotherapy.
- Demonstrated the potential of peptide vaccines in cancer treatment.
- Highlighted challenges in cancer vaccine therapy, including tumor immune evasion and immunosuppression, necessitating further research.